Research

Ongoing research, clinical trials, and additional FDA submissions will combine to enable a revolutionary standard of care for the brain

Initial screening to continuous monitoring

Compared to a functional MRI – the current “gold standard” for brain activity screening and assessment – Neurosteer is inexpensive, portable and unobtrusive. It can be used in a clinical setting for initial assessment and then as part of a patient’s normal daily routine for up to continuous monitoring. It allows the patient to perform cognitive or physical tasks while being monitored and delivers interpreted results in real-time.

Initial screening to continuous monitoring

Compared to an fMRI – the current “gold standard” for functional brain activity screening and assessment – Neurosteer is inexpensive, portable and unobtrusive. It is being investigated for use in a clinical setting for initial assessment and then as part of a patient’s normal daily routine for up to continuous monitoring. It allows the patient to perform cognitive or physical tasks while being monitored and delivers interpreted results in real-time.

Cognitive and Functional

Brain Assessment

Neurosteer’s comprehensive brain assessment platform is currently being validated in multiple clinical studies for the early detection of neurodegenerative disorders, such as Parkinson’s and Alzheimer’s. The system is complemented by a standard 15-minute auditory assessment that can be used to assess multiple brain dysfunctions. The Neurosteer platform is also involved studies to assess the functionality and maturity of newborn brains in premature babies and even babies still in the womb.

Neurosteer is intended for use on subjects who are 18 or older.